Ye Z, et al. - In this meta-analysis of 22,095 patients in 13 randomized controlled trials, researchers investigated the impact of a loading dose of atorvastatin (80 mg) on major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) by comparing a loading dose of atorvastatin to a control in ACS patients who underwent PCI. These studies were identified through searches of medical literature databases. Among overall study participants, loading doses of 80 mg of atorvastatin were administered to 11,214 (50.7%). Findings revealed a significant reduction in MACE, myocardial infarction, revascularization, and stroke with atorvastatin vs control. The two groups had no difference in death or rehospitalization. Overall, significantly reduced cardiovascular events were reported in relation to a loading dose of atorvastatin in patients with ACS.